Docetaxel in the management of ovarian cancer. Issue 2 (April 2005)

• Record Type: Journal Article
• Authors: Blagden, Sarah P; Kaye, Stan B
• Is Part Of: Expert review of anticancer therapy. Volume 5:Issue 2(2005)
• Page Start: 203
• Page End: 214
• Publication Date: 2005-04
• Subjects: docetaxel -- ovarian cancer -- taxane -- paclitaxel; Cancer -- Treatment -- Periodicals; 616.99406
• DOI: 10.1586/14737140.5.2.203
• Languages: English
• ISSNs: 1473-7140

Abstract

Standard first-line treatment for Stage IC–IV ovarian cancer is currently a platinum agent or a combination of a platinum agent with a taxane. The use of a taxane compound in addition to single-agent platinum is increasingly preferred to platinum alone. In countries such as the UK, the taxane paclitaxel has been approved by the government for first-line use. However, it has yet to receive US Food and Drug Administration approval in the USA for use in this context. Typically, in countries such as the UK, patients with advanced ovarian cancer receive a combination of paclitaxel and carboplatin first line, both drugs given 3-weekly by intravenous infusion. Subsequent trials have demonstrated that the second-generation taxane docetaxel can be used as a substitute for paclitaxel; sharing many of its actions but with a different toxicity profile. However, docetaxel has not yet received approval for standard use. Here, the clinical development of docetaxel and its present and future place in the management of ovarian cancer is discussed.